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Central to inflammatory bowel disease (IBD) pathogenesis is loss of mucosal barrier function. Emerging evidence
implicates extracellular adenosine signaling in attenuating mucosal inflammation. We hypothesized that adenosine-
mediated protection from intestinal barrier dysfunction involves tissue-specific signaling through the A2B adenosine
receptor (Adora2b) at the intestinal mucosal surface. To address this hypothesis, we combined pharmacologic studies
and studies in mice with global or tissue-specific deletion of the Adora2b receptor. Adora2b / mice experienced a
significantly heightened severity of colitis, associatedwith amore acute onset of disease and loss of intestinal epithelial
barrier function. Comparison of mice with Adora2b deletion on vascular endothelial cells (Adora2bfl/flVeCadCreþ ) or
intestinal epithelia (Adora2bfl/flVillinCreþ ) revealed a selective role for epithelial Adora2b signaling in attenuating colonic
inflammation. In vitro studies with Adora2b knockdown in intestinal epithelial cultures or pharmacologic studies
highlighted Adora2b-driven phosphorylation of vasodilator-stimulated phosphoprotein (VASP) as a specific barrier
repair response. Similarly, in vivo studies in genetic mouse models or treatment studies with an Adora2b agonist
(BAY60-6583) recapitulate these findings. Taken together, our results suggest that intestinal epithelial Adora2bsignaling
provides protection during intestinal inflammation via enhancing mucosal barrier responses.
INTRODUCTION
Inflammatory bowel disease (IBD) including Crohn’s disease
(CD) and ulcerative colitis (UC) are relapsing-remitting
conditions characterized by uncontrolled intestinal inflamma-
tion and tissue destruction.1 A recent study points to the
increasing incidence and prevalence of both CD and UC in
North America, highlighting the urgent need for effective
therapeutic options.2 Genome-wide association studies have
established a firm link between dysfunction in host–microbial
responses and aberrant mucosal barrier protection with the
development of IBD.1 As such, greater understanding of
dysregulated mucosal homeostasis in IBD may provide novel
therapeutic options.
Release of extracellular adenosine was previously implicated
as an endogenous protective response during mucosal inflam-
mation (reviewed in Aherne et al.3). Adenosine acts through a
number of cell surface receptors to mediate its signaling
responses.3 Studies to date have outlined a role for the A2A
(A2A adenosine receptor (Adora2a))4–7 and A2B (Adora2b)8–13
adenosine receptors in acute inflammation. However, the
functional consequences of adenosine release and signaling
during mucosal inflammation observed in IBD remains to be
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defined. Previous observations indicate that generation of
extracellular adenosine in models of IBD is profoundly
protective.14–16 Adenosine signaling through Adora2a protects
the intestinal mucosa in a chronicmodel of IBD;17 however, the
role of the Adora2b receptor remains undefined. Recent
findings highlight a tissue-protective role for Adora2b signaling
during acute intestinal inflammation as occurs in IBD.12,18
These studies suggest that Adora2b expression at the intestinal
epithelium is a key protective signaling pathway during acute
inflammation. However, in separate studies, intestinal epithe-
lial Adora2b signaling was observed to be deleterious in models
of IBD.19–21 Reasons for these divergent findings have yet to
elucidated, but may be due in part to genetic background
differences in mice studied or in experimental design. We
postulated that Adora2b functions in a tissue-specific manner
at the mucosal surface to mediate protection in intestinal
inflammation. Our aim was to investigate the function of
Adora2b signaling at the mucosal surface during acute inte-
stinal inflammation as experienced during IBD. To examine
this, we generated novel mouse lines with tissue-specific
deletion of the Adora2b receptor. Our studies demonstrated
that mice with global knockout of Adora2b (Adora2b / )
experience rapid, early onset of acute DSS (dextran sulfate
sodium) colitis associated with premature loss of mucosal
barrier function. Tissue-specific murine studies established a
definitive role for intestinal epithelial Adora2b expression
in driving mucosal protection during acute colitis. Supported
by in vitro findings with Adora2b intestinal epithelial knock-
down (KD) cells, we have outlined the Adora2b signaling
pathway as a directly protective mechanism in repairing the
damaged mucosal barrier through phosphorylation of vaso-
dilator-stimulated phosphoprotein (VASP) in the intestinal
epithelium.
Taken together, we observed that tissue-specific expression
of the Adora2b receptor on the intestinal epithelium is an
endogenous protective response to maintain mucosal barrier
function during acute colitis. Pharmacological studies demon-
strate that targeting the Adora2b receptor mediates mucosal
protection from acute intestinal inflammation. This points to
the exciting possibility of exploiting Adora2b signaling in a
tissue-specific manner as a therapeutic approach in IBD.
RESULTS
Mice deficient in Adora2b demonstrate early onset and
increased severity of DSS colitis
The exact role of the Adora2b receptor in IBD remains to be
defined. In previous studies, Adora2b signaling on the intestinal
epithelium was implicated as the relevant signaling path-
way.12,19–21 However, these studies do not agree on whether
Adora2b has a beneficial or deleterious role in models of IBD.
We hypothesized that previous divergent findings may be due
to distinct roles for Adora2b on different stromal tissue.
To investigate this, we assessed mice with whole-body deletion
of Adora2b (Adora2b / ) over the course of DSS colitis.
Decreased survival of Adora2b / mice compared with wild-
type controls (Adora2bþ /þ ) was noted when studies were
performed using 4.5%DSS (Supplementary Figure S1 online).
Owing to high mortality rates in Adora2b / mice at this
percentage, we performed subsequent studies with 3–3.5%DSS.
Monitoring mice during the course of acute colitis revealed
increased weight loss in Adora2b / mice compared with
wild-type controls (Figure 1a). Adora2b / mice exhibited
significantly greater colonic shortening (Figure 1b) and loss of
epithelial barrier function (Figure 1c), as measured by FITC
(fluorescein isothiocyanate)-dextran permeability, compared
with controls, from as early as day 3 following DSS. Upon
termination of the study, Adora2b / mice demonstrated
enhanced neutrophil numbers in the colon (Figure 1d) and
dramatically increased severity of histological disease
(Figure 1e, f). These findings indicate that deficiency of
Adora2b results in earlier onset of tissue damage and loss of
mucosal barrier function during DSS.
Vascular endothelial expression of Adora2b does not have
a role in acute colitis
Drawing fromour findings inAdora2b / mice (Figure 1), we
investigated a tissue-specific role for stromal expression of the
Adora2b receptor using newly developed tissue-specific knockout
mice.Aprevious study implicated vascular endothelialAdora2bas
a key regulator of acute inflammation.8 Mice with deletion of
Adora2b in vascular endothelial cells (Adora2bfl/flVeCadCreþ )
and their wild-type controls (VeCadCreþ ) were exposed to DSS.
Genotyping PCR of tails (not shown) and whole colonic tissues
(Supplementary Figure S2b) demonstrated Cre and Flox
expression in desired tissue.Deletion ofAdora2b in the vascular
endothelium had no effect on acute inflammation experienced
during DSS, as evidenced by no differences in weight loss,
colon length, and histological damage between Adora2bfl/fl
VeCadCreþ and VeCadCreþ mice (Figure 2a–d). These
findings indicate that Adora2b expression on the vascular
endothelium has no significant role in acute intestinal inflam-
mation as observed in IBD.
Specific deletion of intestinal epithelial Adora2b results in
increased severity of acute colitis
Having observed no significant impact of vascular endothelial-
derived Adora2b on the outcome of DSS colitis, we investigated
the function of intestinal epithelial-expressed Adora2b during
acute colitis. Previous findings indicate that Adora2b is
expressed to a high level on intestinal epithelial cells and its
expression is induced during colonic inflammation.22 We
generated mice with deletion of Adora2b in intestinal epithelial
cells (Adora2bfl/flVillinCreþ ) and exposed them along with
wild-type controls (VillinCreþ ) to DSS. Genotyping PCR of
tails (not shown) and colonic intestinal epithelial cells (described
in Flow Cytometry methods: Supplementary Figure S2c)
demonstrated Cre and Flox expression in desired tissue.
Adora2bfl/flVillinCreþ mice exhibited significantly increased
weight loss during the course of DSS compared with VillinCreþ
controls (Figure 3a). Mirroring our findings in whole-body
knockout studies (Figure 1), Adora2bfl/flVillinCreþ mice
experienced significantly greater colonic shortening and
enhanced epithelial barrier permeability at early time points
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following DSS compared with VillinCreþ controls (Figure 3b,
c, respectively). Tissue cytokine analysis revealed a
trend towards an increase in cytokine levels in the tissue of
Adora2bfl/flVillinCreþ mice compared with controls, parti-
cularly in interleukin-6 (IL-6) (Figure 3d). Finally, histological
analysis of the distal colon (Figure 3e, f) demonstrated that
Adora2bfl/flVillinCreþ mice experienced a significantly worse
outcome of DSS colitis compared with wild-type controls. Our
observations highlight a tissue-specific role for expression of
Adora2b on intestinal epithelial cells as a protective response
during the acute phase of intestinal inflammation.
An Adora2b-specific agonist is protective during acute
colitis
Our studies reveal that endogenous expression of Adora2b on
the intestinal epithelium is a protective mechanism during
acute mucosal inflammation. However, the effect of an
exogenous Adora2b agonist during acute colitis has not been
investigated. We undertook studies using a specific Adora2b
agonist (BAY 60-6583). This agonist has previously been
demonstrated to have a high degree of specificity for the
Adora2b receptor.23,24 We confirmed its ability to induce the
second messenger cAMP, a known downstream signaling
molecule of the Adora2b receptor in both CHO (Chinese
hamster ovarian) cells expressing the human Adora2b
receptor and T84 intestinal epithelial cells (Supplementary
Figure S4). Continuous administration of the Adora2b
agonist provided potent tissue protection as measured by
weight loss, colonic shortening, tissue permeability, tissue
cytokine levels, and histological damage of the distal colon in
acute DSS colitis compared with vehicle-treated controls
(Figure 4a–f, respectively). This provides the first evidence
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Figure 1 Adora2b (A2B adenosine receptor)-deficient mice experience early onset of acute colitis. Gender-, age-, and weight-matched Adora2b-
deficientmice (Adora2b / ) or C57BL/6wild-type controls (Adora2bþ /þ ) were exposed to dextran sulfate sodium (DSS) (3–3.5%) over a time course of
7 days. (a) Daily weight measurements were obtained for each group of mice. (b) Following killing, colons were harvested and measured. Results are
representative of one to two independent experiments with n¼ 4–13 mice per group. (c) Mice were administered FITC (fluorescein isothiocyanate)-
dextran by oral gavage (0.6mgg1 at 80mgml1) 4 h before killing. Serum was harvested at killing (days 1 and 3 after DSS) and fluoresence
measurementwas used to determine FITC levels; n¼2–9mice per group fromone independent experiment per timepoint. (d) Following colon harvest at
day 7 after DSS, colonic lamina propria leukocytes were isolated and flow cytometry determined the frequency of GR-1þ (neutrophils), SiglecFþ
(eosinophils), F4/80þ (macrophages), and MHCIIþCD11cHi (dendritic cells) cells. Actual cell number for each cell type was calculated based on the
frequency of cell type multiplied by cell counts following organ harvest. Results are representative of one independent experiment with n¼3–4 mice per
group. (e) Representative histological sections from whole colon of Adora2b / or Adora2bþ /þ mice harvested following 7 days DSS. Bar¼ 100 mm;
images acquired at original magnification  10. (f) Blinded histological analysis of whole colon fromeach group followingDSS.Data represent 8–10mice
per group. Unless stated otherwise, results are representative of two independent experiments with 3–10 mice per group and are displayed as
mean±s.e.m. Two-way analysis of variance (ANOVA) with post hoc Bonferroni t-test was used to determine statistical weight change, but in all other
cases Student’s t-test was used. *Po0.5; **Po0.001; ***Po0.0001.
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that an Adora2b agonist can provide mucosal protection in a
model of IBD.
Adora2b signaling does not effect epithelial barrier
breakdown
To date, we observed premature onset of acute colonic
inflammation in mice deficient in the Adora2b receptor during
DSS colitis (Figure 1). Tissue-specific deletion identified
Adora2b expression on the intestinal epithelium as the key
protective signaling pathway in this model (Figure 3). Con-
sidering that intestinal barrier permeability was significantly
enhanced early in the course of DSS in both Adora2b /
(Figure 1c) and Adora2bfl/flVillinCreþ mice (Figure 3c), we
sought to determine how intestinal epithelial Adora2b might
modulate epithelial barrier breakdown.
A number of intrinsic and extrinsic mechanisms have been
identified that regulate epithelial barrier breakdown during
acute colitis. These include cytokine-induced epithelial barrier
dysfunction,25 alterations in the phosphorylation status of
myosin light chain (MLC),26 nuclear factor-kB (NF-kB)
activity,27 intestinal epithelial cell apoptosis,28 and mucin-2
expression.29 First, we analyzed the effect of Adora2b signaling
on cytokine-induced epithelial barrier breakdown (Figure 5a).
Barrier studies were performed in T84 intestinal epithelial cells
as they express high levels of the Adora2b receptor22 in
comparison with other epithelial cell lines that have been
used to study Adora2b receptor function (Supplementary
Figure S5a).30 T84 intestinal epithelial monolayers were
cotreated with the Adora2b agonist or vehicle and a mixture
of tumor necrosis factor-a (TNFa), IL-1b, and interferon g
(IFNg) (‘‘cytomix’’). Following 72 h of treatment, a FITC-flux
assay was performed to determine the flux rate across the
barrier and thereby the permeability of themonolayer. Adora2b
agonist treatment did not suppress the cytokine-induced
increase in barrier permeability (Figure 5a).
The phosphorylation status of MLC has been demonstrated
to be intimately involved in epithelial tight junction paracellular
permeability,31 with a recent study highlighting a key role for
MLC phosphorylation in intestinal permeability in IBD.26
Treatment of polarized T84 intestinal epithelial monolayers for
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Figure 2 Adora2b (A2B adenosine receptor) in the vascular endothelium does not contribute to DSS (dextran sulfate sodium) colitis disease activity.
Mice with vascular endothelial specific deletion of Adora2b (Adora2bfl/flVeCadCreþ ) were generated and exposed to water or DSS (3%) along with their
wild-type Cre controls (VeCadCreþ ). Following 7 days, mice were killed and the whole colon harvested by blunt dissection. (a) Daily weight
measurements were taken for each group. (b) Upon harvest colon length was measured. (c) Representative whole colonic histological sections are
displayed. Bar¼100 mm; images acquired at original magnification 10. (d) Blinded histological analysis of whole colon from each group followingDSS.
Results are representative of 7–8 mice per DSS group and 2 mice per water group, and are displayed as mean±s.e.m.
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30min (Figure 5b) or 180min (not shown) did not alter MLC
phosphorylation. Of note, an experiment performed with
polarized Caco-2 cells yielded similar findings (not shown).
The master transcription factor NF-kB has a controversial
role in regulating intestinal epithelial barrier function in
acute colitis.27 Studies suggest that adenosine signaling through
the Adora2b receptor inhibits NF-kB transcriptional activ-
ity.24,30,32 In line with previous findings,33 we observed no effect
of cotreatment with the Adora2b agonist on TNFa- (Figure 5c)
or IL-1b- (not shown) induced NF-kB transcriptional activity
in intestinal epithelial cells using an NF-kB-driven luciferase
reporter.
Increased epithelial cell apoptosis may result in loss of
epithelial barrier function during DSS colitis.28,34 TUNEL
(terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate nick end labeling) staining revealed no differences
in the number of apoptotic epithelial cells in the colon of
Adora2bfl/flVillinCreþ mice compared with VillinCreþ con-
trols at the time point when enhanced barrier dysfunction was
observed during DSS (Figure 5d).
Finally, expression of the mucin, Muc-2, has been demon-
strated to be essential in maintaining intestinal epithelial barrier
function.29 Previous findings suggest that adenosine signaling
can upregulate Muc-2 in epithelial cells.35 We observed no
appreciable difference in Muc-2 expression in Adora2b /
mice or Adora2bfl/flVillinCreþ mice compared with their
controls at the time point when barrier dysfunction occurred
(Supplementary Figure S3). Taken together, these findings
suggest that the intestinal epithelial Adora2b receptor does not
protect the epithelial barrier by suppressing cytokine-induced
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Figure 3 Epithelial-specific deletion of the Adora2b (A2B adenosine receptor) receptor results in significantly increased susceptibility to acute colitis.
Mice with intestinal epithelial specific deletion ofAdora2b (Adora2bfl/flVillinCreþ ) were generated and exposed to water or DSS (dextran sulfate sodium,
3–3.5%) along with their wild-type Cre controls (VillinCreþ ). Mice were killed at 3, 4, and 7 days after DSS, and colons harvested by blunt dissection.
(a) Daily weight measurements were assessed for each group of mice. (b) Following harvest at day 3, 4, or 7 colon lengths were measured. Results are
representative of one to two independent experiments per time point with 4–18mice per group. (c)On day 4after DSS, FITC (fluorescein isothiocyanate)-
dextran was administered by oral gavage (0.6mgg1 at 80mgml1) 4 h before killing and serum collection. Fluorescence measurement was used to
determine FITC levels; n¼ 3–8mice per group from one experiment. (d) Following harvest at day 7 after DSS, colon tissue was homogenized and tissue
cytokines were measured by Meso Scale (Meso Scale Discovery, Rockville, MD). Results are displayed normalized to protein content and are
representative of 4–6 mice per group. (e) Representative histological sections from distal colon of Adora2bfl/flVillinCreþ or VillinCreþ mice harvested
following 7 days DSS. Bar¼ 100 mm; images are acquired at original magnification  10. (f) Bar graph of blinded histological scoring of the distal colon
following 7 days of DSS; n¼7–10mice per group. Unless stated otherwise, results are representative of two to three independent experimentswith 4–10
mice per DSS group and are displayed as mean±s.e.m. Two-way analysis of variance (ANOVA) with post hoc Bonferroni t-test was used to determine
statistical weight change, but in all other cases Student’s t-test was used. *Po0.05.
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epithelial barrier permeability, by alteringMLCphosphorylation
status, by altering NF-kB transcriptional activity, or by affecting
either intestinal epithelial cell apoptosis or Muc-2 expression.
Adora2b regulates epithelial barrier resealing
Having observed that Adora2b signaling was not effective in
altering mechanisms associated with enhanced epithelial
barrier breakdown, we directed our studies to look at alternate
mechanisms by which Adora2b receptor signaling could
improve epithelial barrier function. To mimic our in vivo
model, we genetically deleted Adora2b in T84 intestinal
epithelial cells in vitro (Supplementary Figure S5b). We
used a calcium switch assay involving chelation of calcium with
EDTA, which has been demonstrated to cause junction dis-
assembly and a rapid increase in epithelial barrier permeability
that is recoverable by the reintroduction of calcium.36,37 This
allows for the assessment of epithelial junction regulation
during acute disruption of the barrier such as that observed in
DSS. Importantly, this assay allows us to assess the ability of the
epithelial barrier to recover. Barrier recovery was monitored by
measuring the rate at which a FITC-labeled dextran moved
from the apical to the basolateral aspect of epithelial mono-
layers once calcium was reintroduced (Figure 6). The method
bywhich this rate was calculated is discussed in Supplementary
Materials. The rate at which control knockdown (KD) cells or
vehicle-treated cells repair is defined as 1 and data are displayed
as a fold change relative to this rate to account for inter-
experiment variability. Adora2b KD cells demonstrated a
significantly slower recovery of barrier function compared with
their control KD cells (Figure 6a). A previous study implicated
the phosphorylation of the focal adhesion protein VASP at
Ser157 in cAMP-induced epithelial barrier repair following
acute disruption.37 One of the major intracellular pathways
downstream of the Adora2b receptor is the cAMP-protein
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Figure 4 Treatment with an Adora2b (A2B adenosine receptor) agonist mediates mucosal protection observed in a model of acute colitis. Gender-,
age-, andweight-matchedC57BL/6micewere treatedwith anAdora2b-specific agonist (BAY60-6583; 1.2–1.25mgkg1 per day) or vehicle (30%Solutol
HS15 in 0.9%saline) using a subcutaneousosmotic pumpbeginning 1 daybefore administration ofDSS (dextran sulfate sodium, 3.5–4%) for 6 days.Mice
exposed to DSS were orally gavaged with FITC (fluorescein isothiocyanate)-dextran (0.6mgg1 at 80mgml1) 4 h before killing on day 6, serum
collection, and blunt dissection of the colon. (a) Daily weight measurements were obtained for each group ofmice. (b) Colon lengthsweremeasured upon
harvest. (c) Fluorescence measurement determined FITC levels in the serum on day 6 after DSS. (d) Following harvest, cytokines in colonic tissue were
measured by Meso Scale. Results are displayed normalized to protein content and represent 4–5mice per group. (e) Representative colonic histological
images fromvehicle andAdora2b agonist-treatedmiceexposed toDSS.Bar¼ 100mm; imageswere acquired at originalmagnification  10. (f) Bar graph
of blinded histological scoring of the distal colon from vehicle and Adora2b agonist-treated mice exposed to DSS. Results are displayed asmean±s.e.m.
and are representative of one to two independent experiments with 3–7mice per group. Two-way analysis of variance (ANOVA) with post hocBonferroni
t-test was used to determine statistical weight change, but in all other cases Student’s t-test was used. *Po0.5; **Po0.001.
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kinase A (PKA) pathway.3 We have demonstrated that
Adora2b signaling rapidly enhances cAMP levels in T84
intestinal epithelial cells (within 30min: Supplementary
Figure S4c). Within 60min of calcium reintroduction the
epithelial barrier rapidly recovers.37 In this instance, a marked
increase in VASP phosphorylation at Ser157 was observed by
60min, which diminished thereafter.37 We monitored protein
levels of p-VASP (Ser157) and total VASP in our cells at the
indicated time points of recovery (Figure 6b). Of note, the total
VASP antibody also recognizes the phosphorylated form of
VASP, confirming our results with p-VASP (Ser157) antibody.
Western blot confirmed that VASP is phosphorylated at Ser157
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Figure 5 Epithelial Adora2b (A2Badenosine receptor) signaling doesnot affect epithelial barrier breakdown. (a) A combination of tumor necrosis factor-
a (TNFa), interleukin-1b (IL-1b), and interferon g (IFNg) (all 10 ngml1) or media alone was added to the basolateral aspect of polarized T84 intestinal
epithelial cells. Vehicle or the Adora2b agonist (BAY 60-6583; 10 mM) was added to both chambers. Following 72 h, FITC (fluorescein isothiocyanate)-
labeled dextran (3 kDa)was added to the apical chamber anda flux assaywasperformed. Thepermeability of themonolayerwas assessed bymeasuring
the concentration of FITC in the basolateral chamber over time, calculated as the apparent permeability (Papp: cm2 s 1). Results are representative of
three independent experimentswith 2–4wells per group. (b)Confluent T84 intestinal epithelial cellswere treatedon the basolateral andapical aspectwith
vehicle or Adora2b-specific agonist (BAY 60-6583; 10 mM) for 30min before cell harvest and total protein extraction. p-MLC (myosin light chain) (Ser19),
total MLC, and b-actin levels were determined byWestern blot analysis. Results are representative of three independent experiments with 2–3 wells per
experiment. (c) Caco-2 intestinal epithelial cells were transfectedwith an equal amount of a nuclear factor-kB (NF-kB)-responsive promoter attached to a
firefly luciferase reporter (NF-kB-luciferase) and a control reporter vector (Renilla luciferase). Cells were treated in triplicate for 6 h with tumor necrosis
factor-a (TNF-a) (10 ngml1) and theAdora2b agonist (BAY60-6583; 10 mM). Equal volumes of cell lysatewere assayed for luciferase activity. Datawere
normalized to Renilla luciferase and are representative of three independent experiments. (d) Mice with intestinal epithelial specific deletion of Adora2b
(Adora2bfl/flVillinCreþ ) were exposed to water or DSS (dextran sulfate sodium, 3%) along with their wild-type Cre controls (VillinCreþ ) for 4 days and
colons harvested by blunt dissection. Representative images are displayed of apoptotic colonic epithelial cells identified by TUNEL (terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) staining of paraffin-embedded colonic sections. Arrows point to
positively stained cells. Bar¼ 50mm; images were acquired at original magnification  20. Terminal deoxynucleotidyl transferase was omitted as a
negative control. Bar graph of the number of apoptotic colonic epithelial cells in the proximal or distal colon of each group ofmice. The number is displayed
relative to the length of basementmembrane. Scoringwas carried out in ablindedmanner in three randomly selectedmice per group of 6,with a total of six
to eight sections per mouse. All results are displayed as the mean±s.e.m. Statistical analysis was performed using the Student’s t-test.
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Figure 6 Epithelial Adora2b (A2B adenosine receptor) promotes barrier restitution in intestinal epithelial cells. Calcium switch assays were performed
using intestinal epithelial cellswith a fully competent barrier. Cellswere placed in calcium-depleting conditionsuntil barrier functionwas fully compromised
and subsequently allowed to recover in calcium complete media for the time points outlined. (a) Barrier recovery studies were performed with T84
intestinal epithelial cells with constitutive Adora2b knockdown (Adora2b KD) or nonspecific gene KD (control KD) as mentioned. FITC (fluorescein
isothiocyanate)-labeled dextran (10 kDa) was added to the apical aspect of the cells at the start of the recovery period.Media from the basolateral aspect
were sampled every 15min for 105min and fluorescence in the media at each point was measured to analyze rate of barrier restitution. Results are
displayed as fold change in the rate of restitution and represent two independent experiments with 4–6 wells per experiment. (b) Constitutive Adora2b or
control KD cells were used in calcium switch assays as described above and allowed to recover for the indicated times. Total protein was extracted and
phosphorylated vasodilator-stimulated phosphoprotein (p-VASP) (Ser157) and total VASP levels were determined byWestern blot analysis. Results are
representative of three independent experiments with 2 wells per time point per experiment. (c) T84 intestinal epithelial cells were used in calcium switch
assays. Vehicle or theAdora2b-specific agonist (BAY60-6583; 10mM)was added to both the basolateral andapical aspects of the cells at the beginning of
the recovery period. Barrier restitution ratewas determinedas described ina. Results are representative of three independent experimentswith 4–6wells
per experiment. (d) T84 intestinal epithelial cellswere treated as described incand cellswere harvested at different time points during the recovery period
as indicated. Total protein was extracted and p-VASP (Ser157) and total VASP levels were determined by Western blot analysis. Results are
representative of three independent experiments with 2 wells per time point per experiment. (e) Calcium switch assays were performed with T84 cells as
described in c. Cells were allowed to recover for 30min in the presence of vehicle or Adora2b agonist before fixation with 2% paraformaldehyde. Cells
were costainedwith a p-VASP (Ser157) andanE-cadherin antibody followedby fluorescent secondary antibody labeling. Primary antibodieswere omitted
as negative control. Representative images were acquired at original magnification  20. Bar¼50 mm. Results are representative of three independent
experiments with at least 2 wells per group. Results are displayed as mean±s.e.m. Statistical analysis was performed using the Student’s t-test.
*Po0.05.
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during the first 60min of barrier recovery, as observed
previously (Figure 6b).37 Importantly, Adora2b KD cells were
unable to phosphorylateVASP (Ser157) to the same level as their
control cells at time points analyzed and did not exhibit any
alteration in the timecourse of VASP (Ser157) phosphorylation.
In contrast, T84 wild-type cells treated from the onset of
recovery with an Adora2b-specific agonist (BAY 60-6583;
10 mM) exhibited an almost 40% increase in the rate of barrier
recovery compared with vehicle-treated controls (Figure 6c).
We noted a very rapid and sustained elevation of p-VASP
(Ser157) in agonist-treated cells over that in vehicle-treated
controls during barrier recovery (Figure 6d). The position at
which VASP is detected by Western blot makes loading
quantification hard to determine. Therefore, our Western blot
data demonstrate a qualitative trend in alteration of VASP
phosphorylation as a consequence of Adora2b signaling.
Agonist specificity for Adora2b-induced VASP (Ser157)
phosphorylation was confirmed by pretreatment of T84 cells
with a specific Adora2b antagonist before agonist cotreatment.
Under these conditions, the Adora2b agonist failed to
phosphorylate VASP (Ser157) (Supplementary Figure S6).
Finally, we confirmed our Western blot findings by immuno-
fluorescence staining (Figure 6e). We observed a substantial
portion of p-VASP (Ser157) localizing to E-cadherin-positive
T84 epithelial cell junctions within 30min of Adora2b agonist
treatment during barrier recovery compared with vehicle
controls (Figure 6e). This is consistent with a more rapid rate
of barrier recovery in agonist-treated cells (Figure 6c). These
results outline a direct effect of Adora2b signaling on epithelial
barrier function, which our results suggest is mediated through
the phosphorylation of VASP (Ser157).
PKA activity mediates Adora2b-driven VASP (Ser157)
phosphorylation
PKA has been directly implicated in epithelial barrier recovery
and VASP (Ser157) phosphorylation.37 PKA is a known down-
streammediator of Adora2b signaling.3 Treating T84 cells with
the PKA inhibitor (H89; 30 mM) before administration of the
Adora2b-specific agonist (BAY 60-6583; 1 and 10 mM) revealed
a concentration-dependent increase in p-VASP (Ser157) that was
significantly attenuated by the inhibition of PKA (Figure 7a).
Analyzing the Adora2b signaling pathway during barrier
recovery revealed a profound effect of PKA inhibition on the
ability of the Adora2b agonist to phosphorylate VASP (Ser157)
(Figure 7b).We conclude that Adora2b signaling through PKA
plays a significant role in VASP (Ser157) phosphorylation
during barrier recovery.
Epithelial VASP (Ser157) phosphorylation is significantly
diminished in mice deficient in the epithelial Adora2b
receptor during DSS
To assess the relevance of p-VASP (Ser157) in our in vivomodel,
colonic tissue from Adora2bfl/flVillinCreþ and VillinCreþ
mice was stained with p-VASP (Ser157; red) and an epithelial-
specific antibody (E-cadherin; green) at 4 and 7 days after DSS
(Figure 8a, b). 4’,6-diamidino-2-phenylindole (DAPI) (blue)
served as a nuclear counterstain. Of note, the predominant
source of p-VASP (Ser157) staining in the colon was in
E-cadherin-positive cells, indicating that p-VASP (Ser157) is
enriched in the colonic epithelium. In particular, p-VASP
(Ser157) expression was largely observed at the E-cadherin-
positive epithelial cell junctions during DSS (Figure 8a, b).
A profound loss of p-VASP (Ser157) in E-cadherin-positive
epithelial cell junctions was noted in Adora2bfl/flVillinCreþ
compared with VillinCreþ mice at both 4 and 7 days after
DSS (Figure 8a, b, respectively). Differences were quantified
by relating the percentage of p-VASP (Ser157) staining in
E-cadherin-positive areas of the tissue (Figure 8c).
Our data reveal a profound reduction in VASP (Ser157)
phosphorylation in epithelial cells in Adora2bfl/flVillinCreþ
mice compared with VillinCreþ mice in DSS.
An Adora2b agonist induces epithelial VASP (Ser157)
phosphorylation during DSS colitis
We demonstrated that continuous administration of an
Adora2b-specific agonist protects the intestinal epithelial
barrier during acute DSS colitis (Figure 4). In vitro analysis
indicates that Adora2b agonist-mediated induction of VASP
(Ser157) phosphorylation assists in rapid repair of the intestinal
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Figure 7 Epithelial vasodilator-stimulated phosphoprotein (VASP)
(Ser157) phosphorylation is induced by Adora2b (A2B adenosine receptor)
signaling through protein kinase A (PKA). (a) T84 intestinal epithelial cells
were pretreated on both the basolateral and apical aspect of the cell
monolayer with the PKA inhibitor (H89, 30mM) for 45min before 5min
treatment with increasing concentrations of the Adora2b-specific agonist
(BAY 60-6583; 1 and 10mM) in the presence or absence of the PKA
inhibitor. Cells were harvested, total protein extracted, and p-VASP
(Ser157) and total VASP levels were determined byWestern blot analysis.
(b) Calcium switch assays were performed using T84 intestinal epithelial
cells with a fully competent barrier. Cells were placed in calcium-depleting
conditions until barrier function was fully compromised and subsequently
allowed to recover in calcium complete media for the time points outlined.
Cells were treated on both the basolateral and apical aspect with the
Adora2b-specific agonist (BAY 60-6583; 10mM) in the presence or
absence of the PKA inhibitor (H89, 30mM) from the beginning of the
recovery period for the time points indicated. Cells were harvested, total
protein extracted, and p-VASP (Ser157) and total VASP levels were
determined by Western blot analysis. Results are representative of three
independent experiments with 2–3 wells per time point per experiment.
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Figure 8 Loss of epithelial Adora2b (A2B adenosine receptor) expression results in significantly reduced localization of p-VASP (phosphorylated
vasodilator-stimulated phosphoprotein) (Ser157) to the intestinal epithelial barrier during acute colitis. Mice with intestinal epithelial-specific deletion of
Adora2b (Adora2bfl/flVillinCreþ ) were exposed to DSS (dextran sulfate sodium) (3%) along with their wild-type Cre controls (VillinCreþ ). Following 4
and 7 days DSS, colons were harvested by blunt dissection and formalin fixed. (a and b) Formalin-fixed colons were deparaffinized and rehydrated.
Slides were costained with p-VASP (Ser157) and E-cadherin antibodies and appropriate fluorescent secondary antibodies. DAPI (4’,6-diamidino-2-
phenylindole) served as a nuclear counterstain. Omission of primary antibodies was used as a negative control. Representative imageswere acquired at
original magnification 20. Bar¼ 50mm. (c) p-VASP (Ser157) costaining of E-cadherin-positive cells was calculated using Olympus software (Shinjuku,
Tokyo, Japan). Image analysis was performed in a blinded manner using images acquired at the same settings, with a defined threshold of intensity
applied to all images. Results represent the percentage staining of three identically sized randomly selected E-cadherin-positive regions of interest from
each image. Day 4 results represent one image permousewith fourmice in each group. Day 7 results represent 4–5 images permousewith 5–7mice per
group. Data are displayed as the mean±s.e.m. Statistical analysis was performed using the Student’s t-test. *Po0.05 and ***Po0.0001.
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epithelial barrier (Figure 6c, d).We therefore analyzed p-VASP
(Ser157) expression in vivo followingAdora2b agonist treatment
during DSS (Figure 9). Immunofluorescence analysis was
performed in colonic tissue following vehicle or Adora2b
agonist administration for 6 days during DSS, as discussed
above (Figure 4). Adora2b agonist-treated mice exhibited a
significantly higher level of p-VASP (Ser157) expression in
E-cadherin-positive cells in comparison with vehicle-treated
mice (Figure 9a). A large portion of epithelial p-VASP (Ser157)
was observed to localize to E-cadherin-positive epithelial cell
junctions following Adora2b agonist treatment (Figure 9a).
p-VASP (Ser157) levels in the epithelium were quantified
by measuring the percentage of staining in standardized
sections of E-cadherin-positive tissue (Figure 9b). These find-
ings indicate that an Adora2b agonist can induce epithelial
VASP (Ser157) phosphorylation to facilitate a barrier-protective
response in DSS colitis.
DISCUSSION
Current studies point to the key role played by dysregulated
mucosal homeostasis in the development of IBD.1 As such,
better understanding of mucosal responses in the context of
IBD is of great relevance to the identification of novel
therapeutic options.
The release of adenosine from inflamed tissues and its
receptor signaling pathways have been highlighted as an
endogenous mechanism to dampen inflammation.3 In the
context of IBD, maintaining high tissue levels of adenosine has
been demonstrated to protect the intestinal mucosa.14–16
However, the predominant adenosine receptor signaling
pathway that mediates protection during IBD remains to be
elucidated. There is evidence that adenosine signaling through
the Adora2a receptor is protective in a T-cell-mediated murine
model of IBD.17,38 However, anAdora2a agonist was ineffective
in an acute colitis model, indicating a potential tissue- and
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Figure 9 Adora2b (A2B adenosine receptor) agonist treatment results in significantly increased localization of p-VASP (phosphorylated vasodilator-
stimulated phosphoprotein) (Ser157) to the intestinal epithelial barrier in vivo during DSS (dextran sulfate sodium) colitis. Gender-, age-, and weight-
matched C57BL/6 mice were treated with an Adora2b-specific agonist (BAY 60-6583; 1.2–1.25mg/kg1 per day) or vehicle for 6 days during DSS as
described in Figure 4. Colons were harvested by blunt dissection and formalin fixed. (a) Formalin-fixed colons were deparaffinized and rehydrated.
Sections were costained with p-VASP (Ser157) and E-cadherin antibodies as described in Figure 7a and b. Representative images were acquired at
original magnification  20. Bar¼ 50mm. (b) p-VASP (Ser157) staining of E-cadherin-positive cells was calculated as described inFigure 7c. Results are
representative of 1–3 images permousewith 5–7mice per group. Statistical analysis was performed using the Student’s t-test. Data are displayed as the
mean±s.e.m. ***Po0.0001.
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context-specific role for adenosine signaling in the inflamed
intestine.39 This is further highlighted when considering the
potential role of the Adora2b adenosine receptor in IBD.
To date, studies have indicated both a protective12,18 and
deleterious effect19–21 of Adora2b receptor signaling at the level
of the intestinal epithelium in murine models of colitis.
Divergent results observed may be because of specific effects of
Adora2b signaling at alternative stromal tissue sites. Indeed
vascular endothelial expression of the Adora2b receptor has
been demonstrated to be an important protective pathway in
another model of acute mucosal inflammation.8 Therefore, we
were interested in defining the Adora2b signaling events
occurring on stromal tissue during acute intestinal inflamma-
tion. We postulated that the Adora2b receptor had a tissue-
specific role to play during the development of IBD.
To dissect the role of Adora2b on stromal tissue during acute
colitis, we examined mice lacking the Adora2b receptor
(Adora2b / ) over a time course of DSS (Figure 1). We
observed significant increases in disease activity parameters
early in the time course of disease in Adora2b / mice
compared with wild-type controls (Figure 1). As early as day 3,
Adora2b / mice exhibited pronounced colonic shorten-
ing and loss of epithelial barrier function (Figure 1b, c,
respectively). This culminated in considerably greater
histological disease (Figure 1e–f) and robust recruitment of
neutrophils to the colonic lamina propria ofAdora2b / mice
in comparison with wild-type controls (Figure 1d). Taken
together, our findings suggest a protective role for Adora2b
signaling during acute intestinal inflammation.
Previous findings in a model of hypoxia-driven inflamma-
tion indicate that Adora2b receptors on the vascular endothe-
lium mediate a protective response in acute inflammation.8
Using a novelAdora2b-floxmouse line, we generatedmice with
tissue-specific deletion of Adora2b on the vascular endothe-
lium. These mice did not exhibit any alteration in disease
outcome compared with their genetic controls during DSS
colitis (Figure 2), prompting us to consider an alternative
stromal source of Adora2b-mediated mucosal protection.
Intestinal epithelial cells express a high level of the Adora2b
receptor, which can be upregulated by mediators associated
with colitis.22 Using a tissue-specific gene approach, we
demonstrated that genetic loss of Adora2b in intestinal
epithelial cells led to significantly greater disease activity
during DSS (Figure 3). As in whole-body Adora2b deletion
(Figure 1), we observed pronounced early onset of disease in
mice lacking epithelial Adora2b (Adora2bfl/flVillinCre)
culminating in worsened DSS colitis outcome in Adora2bfl/fl
VillinCre mice in all parameters measured (Figure 3).
Given our current findings, we hypothesized that pharma-
cologic targeting of the Adora2b receptor may be of therapeutic
benefit in acute colitis. Mice administered an Adora2b-specific
agonist were profoundly protected from development of DSS
colitis (Figure 4). Importantly, Adora2b agonist treatment
improved intestinal epithelial barrier function (Figure 4c),
suggesting agonist-directed mucosal protection in acute colitis.
While previous studies illustrated that anAdora2b antagonist is
deleterious in colitis,12 this is the first study demonstrating that
Adora2b signaling can be therapeutically targeted for tissue
protection in a model of IBD.
Our observations to date suggest that endogenous epithelial
Adora2b is a barrier-protective signaling pathway in acute
colitis.We therefore concentrated our efforts on elucidating the
functional role of the Adora2b receptor on the intestinal
epithelium during the acute response in DSS. Generally, DSS
colitis is characterized by elevated tissue cytokine levels,
enhanced epithelial cell apoptosis, and loss of intestinal barrier
function.28,40,41 We pursued studies to interrogate the role of
the Adora2b receptor in processes known to be involved in
these features of early mucosal barrier dysfunction. Previous
study suggests that Adora2b signaling induces the release of the
proinflammatory cytokine, IL-6,42 and the anti-inflammatory
cytokine, IL-10,12 from the intestinal epithelium. Adora2bfl/fl
VillinCre mice were observed to have a slightly elevated tissue
content of IL-6 but no significant alteration in IL-10 compared
with control mice (Figure 3d). In contrast, Adora2b agonist-
treatedmice exhibited a significant decrease in IL-6 tissue levels
and a reduction in IL-10 compared with vehicle controls
(Figure 4d). Taking these findings in the context of the previous
studies mentioned, our results suggest that direct regulation of
cytokine release at the epithelium was not the predominant
function of the epithelial Adora2b receptor in our model. We
next investigated the potential role of Adora2b receptor
signaling in mechanisms that promote epithelial barrier
breakdown during DSS colitis. However, we failed to
observe an effect of Adora2b signaling on cytokine-induced
epithelial barrier permeability, MLC phosphorylation,
NF-kB transcriptional activation, epithelial cell apoptosis
(Figure 5a–d, respectively), or mucin-2 expression (Supple-
mentary Figure S3). These studies were predominantly per-
formed in vitro and were used to direct additional in vitro and
in vivo studies. We cannot abandon the possibility that one of
themechanisms excluded by our in vitro studiesmay contribute
to the phenotype we observe in our animal model.
Having ruled out direct effects of epithelial Adora2b receptor
signaling on epithelial cytokine release and processes impli-
cated in epithelial barrier breakdown, we considered a potential
role for the Adora2b in mechanisms involved in epithelial
barrier repair. To do this, we used an in vitro model with
polarized intestinal epithelial cells. First, we confirmed the
capability of the Adora2b-specific agonist to induce known
receptor second messenger pathways and demonstrated
efficient increase in intracellular cAMP following agonist
treatment (Supplementary Figure S4). We subsequently
generated genetic knockout of Adora2b in intestinal
epithelial cells to mirror our in vivo model (Supplementary
Figure S5b). To model epithelial tight junction rearrangement
and barrier dysfunction observed in IBD, we used a calcium
switch assay in vitro.36,37 Importantly, in this model epithelial
junction reassembly and repair can be studied. Adora2b KD
cells exhibited impaired recovery of barrier function following
junction disassembly (Figure 6a), whereas agonist treatment
during recovery significantly enhanced the rate of barrier
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restitution when compared with vehicle treatment (Figure 6c).
Considering our observations that Adora2b signaling was
capable of enhancing barrier recovery (Figure 6) and also
elevated intracellular cAMP (Supplementary Figure S4), we
noted that cAMP-mediated phosphorylation of VASP had
previously been implicated in recovery of epithelial barrier
function.37 In this study, expression of VASP in the intestinal
epithelium was demonstrated to be necessary for the recovery
of epithelial barrier function, with phosphorylated VASP
(p-VASP Ser157) localizing to the junction during barrier
recovery. Using these previous findings, we examined our
Adora2b-deficient cells and demonstrated an appreciable
decrease in the level of p-VASP (Ser157) during barrier recovery
compared with control cells (Figure 6b). In addition, Adora2b
agonist treatment of wild-type cells enhanced p-VASP (Ser157)
expression during barrier recovery over that in vehicle-treated
cells (Figure 6d). Importantly, an increased level of p-VASP
(Ser157) was observed to colocalize with E-cadherin within
30min of recovery following agonist treatment compared with
vehicle, suggesting an accumulation of this protein at the
repairing junction (Figure 6e). Using a PKA antagonist, we
demonstrated that induction of PKA was a major pathway
by which the Adora2b receptor induced VASP (Ser157)
phosphorylation either in intact or repairing epithelial cells
(Figure 7).
Having identified the phosphorylation of VASP (Ser157) as a
likely mechanism by which the Adora2b receptor repairs the
intestinal epithelial barrier in vitro, we wanted to investigate the
potential relevance of this in vivo. Adora2bfl/flVillinCre mice
demonstrated a significantly diminished expression of p-VASP
(Ser157), particularly at epithelial cell junctions during the early
onset of DSS (day 4; Figure 8a). This was also the case following
the complete time course of DSS (day 7; Figure 8b). Early loss
of p-VASP (Ser157) in the epithelial junctions coincided with
our observation of enhanced epithelial barrier permeability
in Adora2bfl/flVillinCre mice compared with control mice
(Figure 3c). In contrast, mice treated with the Adora2b agonist
during DSS were observed to have a pronounced increase in
p-VASP (Ser157) at epithelial cell junctions compared with
vehicle-treated controls (Figure 9). This matched with our
finding of significantly reduced epithelial barrier permeability
in agonist-treated mice compared with vehicle controls at the
same time point (Figure 4c). These observations suggest that
Adora2b signaling in the intestinal epithelium in vivo regulates
VASP (Ser157) phosphorylation to enhance epithelial barrier
function during acute inflammation. Of note, we did not
analyze the expression of other junctional proteins in these
mice and therefore cannot exclude the possibility that in vivo
Adora2b signaling may have additional effects on epithelial
junction proteins.
In this study, we used a whole-body and tissue-specific
genetic approach to define the contribution of Adora2b to
mucosal inflammation. Initial studies in mice with whole-body
deletion of Adora2b (Adora2b / ) demonstrated rapid, early
onset of mucosal inflammation in Adora2b / mice during
experimental colitis. Excitingly, we determined that intestinal
epithelial-specific Adora2b signaling is a key pathway in
mediating mucosal barrier protection during acute colitis.
In vitro and in vivo analysis points to Adora2b phosphorylation
of VASP (Ser157) and its localization to epithelial cell junctions
as a potential mechanism by which endogenous Adora2b
mediates a barrier protective effect. Herein, we present novel
studies demonstrating for the first time that Adora2b signaling
can be exploited as a therapeutic pathway in a model of IBD.
Taken together, we have defined that specific signaling through
intestinal–epithelial Adora2b receptors provides potent pro-
tection during acute intestinal inflammation, an important
finding that may be exploited as a novel therapeutic strategy in
IBD.
METHODS
DSS colitis. Adora2b-deficient mice,8 mice with tissue-specific
Adora2b deletion (for more details see Supplementary Materials),
matched genetic controls, or C57BL/6 mice were used in DSS studies
(3–4.5%), as described previously.13,44,45 Adora2b agonist (BAY 60-
6583; Tocris Bioscience, Bristol, UK) or vehicle (30% SolutolHS15 in
0.9% saline; BASF, Florham Park, NJ) was administered by sub-
cutaneous osmotic pump (Alzet; DURECT Corporation, Cupertino,
CA) at 1.2–1.25mg kg 1 mouse per day.
Flowcytometric analysis. Flow cytometric analysis of lamina propria
leukocytes was performed with antibodies against GR-1 (RB6-8C5),
SiglecF (E50-2440), F4/80 (BM8), CD11c (N418), MHCII (M5/
114.15.2), and CD45 (30-F11), as outlined previously.13,43
In vivo permeability. Tissue permeability was measured using
FITC-labeled dextran as described previously.13
Cell culture and generation of short hairpin RNA KD. Cells were
cultured as outlined in Supplementary Materials.30,46–48 Constitutive
KD of Adora2b was generated using MISSION shRNA technology
(as described in Supplementary Materials).
In vitro FITC-dextran flux assay. FITC-dextran (3 kDa) flux assays
were performed in T84 intestinal epithelial cells following cytomix
treatment (TNFa, IL-1b, and IFNg; 10ng/ml) in the presence of vehicle
or Adora2b agonist (BAY 60-6583, 10 mM) as described13,49 (for more
details see Supplementary Materials).
Luciferase reporter assay. Caco-2 intestinal epithelial cells were
transfected with equal amounts of NF-kB luciferase and Renilla
luciferase plasmids. Following 24 h, cells were treated with vehicle,
TNFa (10 ng/ml), the Adora2b agonist alone (BAY 60-6583, 10 mM), or
in combinationwithTNFa. Luminescencewas detected as described in
Supplementary Materials.
TUNEL staining. Apoptotic epithelial cells were detected by TUNEL
staining of formalin–fixed, paraffin-embedded tissue (for details see
Supplementary Materials).
Calcium switch assay. Calcium switch assays in T84 intestinal
epithelial cells were performed as outlined previously.36 Barrier
restitution rate was determined by the addition of FITC-dextran
(10 kDa) to the apical aspect at the time of recovery and sampling of
FITC in the basolateral compartment (for further details see
Supplementary Methods).
Western blot analysis. Equal amounts of whole-cell lysates were
separated by gel electrophoresis, transferred, and membranes incu-
bated with either anti-human p-VASP (Ser157) (Cell Signaling,
Danvers, MA), anti-human anti-VASP (BD Transduction Labora-
tories, San Jose, CA), anti-human p-MLC-2 (Ser19) (Cell Signaling),
anti-human MLC-2 (Cell signaling), or anti-actin (Calbiochem).
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Immunofluorescence. Paraffin-embedded sections or paraformalde-
hyde fixed cell membranes were incubated with anti-human p-VASP
(Ser157) or anti-human E-cadherin followed by fluorescent detection.
Statistical analysis. GraphPad Prism Analysis software (GraphPad
Software, La Jolla, CA) was used to perform statistical analysis.
Analysis of variance (ANOVA) followed by post-test or Student’s t-test
was used where appropriate and results are expressed as mean±s.e.m.
For further details see Supplementary Materials.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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